Schizophrenia News and Research

Latest Schizophrenia News and Research

First Edition: January 21, 2011

Today's headlines highlight the House GOP's plans to advance the "replace" part of their strategy to reverse the health overhaul.

21 Jan 2011

RBM, SMA Foundation collaborate to develop plasma protein biomarkers for spinal muscular atrophy

The Spinal Muscular Atrophy Foundation and Rules-Based Medicine, announced today that they have reached the first milestone in a program to develop a panel of plasma protein biomarkers for SMA using RBM's Multi-Analyte Profiling technology platform.

21 Jan 2011

Roundup: Medicaid cuts and waivers; Mental health care; Mass. immigrant care; Minn. medical errors

Local hospitals facing a possible 10 percent cut in Medicaid fees plan to pressure commercial health insurers for better rates, which could drive up costs for everyone. Texas House Republicans unveiled a budget this week that takes aim at Medicaid, the state's second-largest program, behind public education.

21 Jan 2011

First Edition: January 20, 2011

Today's headlines feature reports about yesterday's House vote to repeal the health overhaul and about the GOP's next steps in its effort to undo the sweeping law.

20 Jan 2011

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Targacept, Inc. today announced positive top-line results from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia.

20 Jan 2011

BSi and OMJPI enter development agreement for novel neurological and psychiatric disease therapeutics

The Johns Hopkins Brain Science Institute (BSi) announced today that it has entered into an agreement with Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI) to advance the development of novel therapeutics for neurological and psychiatric diseases.

19 Jan 2011

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

The Scripps Research Institute has been awarded $3.17 million over four years to develop compounds that will counteract disruptions of the human biological clock - the circadian rhythm that regulates our patterns of activity and rest over a 24-hour daily cycle.

19 Jan 2011

Alexza completes FDA review for AZ-004 NDA

Alexza Pharmaceuticals, Inc. announced today that it completed an End-of-Review meeting with the U.S. Food and Drug Administration (FDA or Agency) for the AZ-004 New Drug Application (NDA), and has received the official FDA minutes from the meeting. In December 2010, Alexza held the End-of-Review meeting in response to a Complete Response Letter (CRL) received in October 2010.

18 Jan 2011

Biological Psychiatry publishes special issue focusing on postmortem studies of psychosis

Biological Psychiatry is proud to announce this week's publication of a special issue focusing on postmortem studies of psychosis. This special issue showcases the use of human brains postmortem to study psychiatric disorders, focusing on schizophrenia. The review articles highlight the benefits, achievements, problems, and perhaps most importantly, the future of postmortem research.

18 Jan 2011

OMJPI, Sanford-Burnham enter agreement to discover compounds for Alzheimer's disease, psychiatric disorders

Sanford-Burnham Medical Research Institute has entered into a collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to discover compounds for Alzheimer's disease and major psychiatric disorders.

18 Jan 2011

Eating less during early pregnancy impairs fetal brain development: Study

Eating less during early pregnancy impaired fetal brain development in a nonhuman primate model, researchers from The University of Texas Health Science Center San Antonio reported today.

18 Jan 2011

UCLA imaging system could help reveal 'miscommunications' in autism, schizophrenia

Some disorders of the brain are obvious - the massive death of brain cells after a stroke, the explosion in the growth of cells that marks a tumor. Other disorders, such as autism, schizophrenia and mental retardation show no physical signs of damage and are believed to be caused by problems in how brain cells communicate with one another.

13 Jan 2011

CAMH scientists receive NARSAD's Young Investigator grant awards for brain and behavior research

Seven scientists at Canada's Centre for Addiction and Mental Health have been awarded Young Investigator grant awards by the U.S.-based NARSAD: The Brain and Behavior Research Fund.

12 Jan 2011

Nicotine may act as treatment for some symptoms of schizophrenia

Smoking is a common problem for patients with schizophrenia. The increased tendency of patients diagnosed with this disorder is to not only smoke, but to do so more heavily than the general public. This raises the possibility that nicotine may be acting as a treatment for some symptoms of schizophrenia.

11 Jan 2011

Mithridion secures commitments of $1.25 million in new funding

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease, announces that it has secured commitments of $1.25 million in new funding.

11 Jan 2011

ACADIA raises $15 million through private placement

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a securities purchase agreement for a private placement financing with a select group of institutional investors, including New Enterprise Associates and Venrock.

10 Jan 2011

Unexpected discovery holds promise for PTSD, other anxiety disorders

An unexpected discovery by UCLA life scientists holds promise for the future development of treatments for post-traumatic stress disorder and other anxiety disorders, and potentially for Alzheimer's disease and other memory-impairment diseases.

7 Jan 2011

NARSAD awards $12.6 million for mental health research

NARSAD: The Brain and Behavior Research Fund awards $12.6 million in new research grants, strengthening its investment in the most promising ideas to lead to breakthroughs in understanding and treating mental illness.

7 Jan 2011

Breakthrough in MRI allows brain scans more than seven times faster

An international team of physicists and neuroscientists has reported a breakthrough in magnetic resonance imaging that allows brain scans more than seven times faster than currently possible.

6 Jan 2011

Study on aberrant cellular localization in the brain

Normally, cortical nerve cells or neurons reside in the brain's gray matter with only a few scattered neurons in the white matter, but some people with schizophrenia have a higher number of neurons in the white matter. Neuronal migration errors may arise in schizophrenia as a consequence of both genetic and environmental factors.

5 Jan 2011

Schizophrenia News and Research

Latest Schizophrenia News and Research

First Edition: January 21, 2011

RBM, SMA Foundation collaborate to develop plasma protein biomarkers for spinal muscular atrophy

Roundup: Medicaid cuts and waivers; Mental health care; Mass. immigrant care; Minn. medical errors

First Edition: January 20, 2011

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

BSi and OMJPI enter development agreement for novel neurological and psychiatric disease therapeutics

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

Alexza completes FDA review for AZ-004 NDA

Biological Psychiatry publishes special issue focusing on postmortem studies of psychosis

OMJPI, Sanford-Burnham enter agreement to discover compounds for Alzheimer's disease, psychiatric disorders

Eating less during early pregnancy impairs fetal brain development: Study

UCLA imaging system could help reveal 'miscommunications' in autism, schizophrenia

CAMH scientists receive NARSAD's Young Investigator grant awards for brain and behavior research

Nicotine may act as treatment for some symptoms of schizophrenia

Mithridion secures commitments of $1.25 million in new funding

ACADIA raises $15 million through private placement

Unexpected discovery holds promise for PTSD, other anxiety disorders

NARSAD awards $12.6 million for mental health research

Breakthrough in MRI allows brain scans more than seven times faster

Study on aberrant cellular localization in the brain

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Schizophrenia News and Research

Latest Schizophrenia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in